Development of Passive Immunotherapies for Synucleinopathies

  • Bergström A
  • Kallunki P
  • Fog K
  • 30


    Mendeley users who have this article in their library.
  • 17


    Citations of this article.


Immunotherapy using antibodies targeting alpha-synuclein has proven to be an effective strategy for ameliorating pathological and behavioral deficits induced by excess pathogenic alpha-synuclein in various animal and/or cellular models. However, the process of selecting the anti-alpha-synuclein antibody with the best potential to treat synucleinopathies in humans is not trivial. Critical to this process is a better understanding of the pathological processes involved in the synucleinopathies and how antibodies are able to influence these. We will give an overview of the first proof-of-concept studies in rodent disease models and discuss challenges associated with developing antibodies against alpha-synuclein resulting from the distribution and structural characteristics of the protein. We will also provide a status on the passive immunization approaches targeting alpha-synuclein that have entered, or are expected to enter, clinical evaluation.

Author-supplied keywords

  • Alpha-synuclein
  • Parkinson's disease, synucleinopathies
  • mechanism of action
  • passive immunization

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Ann Louise Bergström

  • Pekka Kallunki

  • Karina Fog

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free